• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BetterInvesting™ Magazine Update on Stride Inc. (NYSE: LRN) and Amgen Inc. (NASDAQ: AMGN)

    5/27/25 10:18:00 PM ET
    $AMGN
    $LRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Other Consumer Services
    Real Estate
    Get the next $AMGN alert in real time by email

    TROY, Mich., May 27, 2025 /PRNewswire/ -- Stride Inc.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Stride Inc. (NYSE:LRN) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for investors' informational and educational use.

    The fundamental data is eye-opening; investors can view Stride's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., here. 

    A full report on Stride will appear in the August 2025 issue of BetterInvesting Magazine. 

    The same issue of BetterInvesting Magazine will also include a fundamental review of Amgen Inc. (NASDAQ:AMGN), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. 

    Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

    Doron P. Levin, an editor of the magazine, serves as the committee's chairperson.

    Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn, Instagram and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-stride-inc-nyse-lrn-and-amgen-inc-nasdaq-amgn-302466516.html

    SOURCE NAIC-BetterInvesting

    Get the next $AMGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMGN
    $LRN

    CompanyDatePrice TargetRatingAnalyst
    Amgen Inc.
    $AMGN
    2/20/2026$185.00Equal Weight
    Barclays
    Amgen Inc.
    $AMGN
    1/20/2026$335.00Outperform → Mkt Perform
    Bernstein
    Amgen Inc.
    $AMGN
    1/7/2026$380.00Buy
    UBS
    Amgen Inc.
    $AMGN
    12/5/2025Hold → Buy
    Erste Group
    Amgen Inc.
    $AMGN
    11/24/2025$318.00Hold
    Truist
    Amgen Inc.
    $AMGN
    11/13/2025$385.00Sector Outperform
    Scotiabank
    Stride Inc.
    $LRN
    10/29/2025$108.00Outperform → Market Perform
    BMO Capital Markets
    Amgen Inc.
    $AMGN
    9/3/2025Mkt Perform
    Raymond James
    More analyst ratings

    $AMGN
    $LRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Amgen with a new price target

    Barclays initiated coverage of Amgen with a rating of Equal Weight and set a new price target of $185.00

    2/20/26 8:23:35 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amgen downgraded by Bernstein with a new price target

    Bernstein downgraded Amgen from Outperform to Mkt Perform and set a new price target of $335.00

    1/20/26 10:22:04 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Amgen with a new price target

    UBS resumed coverage of Amgen with a rating of Buy and set a new price target of $380.00

    1/7/26 9:08:42 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $LRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enrollment Opens for K12-Powered Virtual Public Schools Serving Students Across Washington

    OLYMPIA, WA, March 06, 2026 (GLOBE NEWSWIRE) -- Enrollment is now open for the 2026–2027 school year at the following K12-powered tuition-free virtual public schools serving students across Washington:  Insight School of Washington (ISWA), serving grades K–12 Washington Virtual Academies (WAVA), serving grades K–12  Each school is a full-time online public school taught by state-certified teachers and aligned to Washington academic standards. The schools are powered by K12, a national leader in online public education and provide:  Washington-certified teachers delivering live, interactive instructionCareer and technical education (CTE) pathways that allow high school students

    3/6/26 10:00:00 AM ET
    $LRN
    Other Consumer Services
    Real Estate

    AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE

    THOUSAND OAKS, Calif., March 5, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference at 9:20 a.m. ET on Wednesday, March 11, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jasper van Grunsven, senior vice president of rare disease at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferenc

    3/5/26 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Enrollment Opens for K12-Powered Virtual Public Schools Serving Students Across Oregon

    SALEM, OR, March 05, 2026 (GLOBE NEWSWIRE) -- Enrollment is now open for the 2026–2027 school year at the following K12-powered tuition-free virtual public schools serving students across Oregon:  Cascade Virtual Academy (CVA), serving grades K–12 Destinations Career Academy of Oregon (ORDCA), serving grades 9–12 Insight School of Oregon–Painted Hills (ISOR-PH), serving grades 7–12  Each school is a full-time online public school taught by state-certified teachers and aligned to Oregon academic standards. The schools are powered by K12, a national leader in online public education and provide: Oregon-certified teachers delivering live, interactive instructionCareer and technic

    3/5/26 11:45:57 AM ET
    $LRN
    Other Consumer Services
    Real Estate

    $AMGN
    $LRN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    8/21/24 12:12:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $LRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, CEO and President Bradway Robert A covered exercise/tax liability with 84,285 shares and exercised 119,782 shares at a strike of $156.35, increasing direct ownership by 8% to 492,643 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    3/6/26 7:32:13 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, Operations Santos Esteban was granted 11,259 shares, increasing direct ownership by 15% to 87,877 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    3/5/26 8:43:34 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP & Chief Technology Officer Reese David M was granted 12,063 shares, increasing direct ownership by 34% to 47,650 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    3/5/26 8:42:19 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $LRN
    SEC Filings

    View All

    SEC Form 25-NSE filed by Amgen Inc.

    25-NSE - AMGEN INC (0000318154) (Subject)

    2/24/26 4:30:56 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Amgen Inc.

    8-K - AMGEN INC (0000318154) (Filer)

    2/19/26 4:27:56 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form FWP filed by Amgen Inc.

    FWP - AMGEN INC (0000318154) (Subject)

    2/17/26 5:14:08 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $LRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Amgen Inc converted options into 33,603,948 shares and bought $29,999,985 worth of shares (1,764,705 units at $17.00)

    4 - AMGEN INC (0000318154) (Reporting)

    9/19/23 7:52:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $LRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stride Inc.

    SC 13G/A - Stride, Inc. (0001157408) (Subject)

    10/31/24 11:54:57 AM ET
    $LRN
    Other Consumer Services
    Real Estate

    SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

    SC 13G/A - AMGEN INC (0000318154) (Subject)

    2/13/24 4:58:51 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

    SC 13G/A - AMGEN INC (0000318154) (Subject)

    1/30/24 11:35:57 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $LRN
    Leadership Updates

    Live Leadership Updates

    View All

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolioBrings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appoi

    7/21/25 7:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Opening Doors to Healthcare Careers: McKallen Medical Training Center Partners with MedCerts to Expand Access to Training Programs for Aspiring Healthcare Professionals

    ONTARIO, California, Nov. 13, 2024 (GLOBE NEWSWIRE) -- As the demand for skilled healthcare professionals surges in California, McKallen Medical Training Center (MMTC) is stepping up to meet the challenge. MMTC is teaming up with MedCerts, a recognized leader in online healthcare training, to offer a wide range of certification training courses to aspiring healthcare workers. This collaboration will provide students with access to quality, flexible online certification training in critical areas like Medical Assistant, Patient Care Technician and more, helping to fill essential roles in California's rapidly growing healthcare industry. MMTC currently offers programs at its locations in

    11/13/24 9:00:00 AM ET
    $LRN
    Other Consumer Services
    Real Estate

    $AMGN
    $LRN
    Financials

    Live finance-specific insights

    View All

    AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

    THOUSAND OAKS, Calif., March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026. The dividend will be paid on June 5, 2026, to all stockholders of record as of the close of business on May 15, 2026.About AmgenAmgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge

    3/4/26 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

    THOUSAND OAKS, Calif., Feb. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024. "Amgen delivered strong performance in 2025, with double-digit growth in revenues and earnings per share. We enter 2026 with momentum across a broad portfolio of medicines and a clear path towards advancing innovative therapies to deliver sustained long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the fourth quarter, total revenues increased 9% to $9.9 billion in comparison to the fourth quarter of 2024.Product sales grew 7%, driven by 10% volume gro

    2/3/26 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

    THOUSAND OAKS, Calif., Jan. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public. The webcast, as with other sel

    1/28/26 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care